Core One Labs Files Application to List its Common Shares on NASDAQ
VANCOUVER, British Columbia, March 20, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN:...
Day: March 21, 2021
89bio Presents Additional Analysis of Phase 1b/2a NASH Study at the Annual ENDO 2021 Conference
New analysis shows BIO89-100 meaningfully reduces liver fat volume and liver volume in patients with NASHSAN FRANCISCO, March 20, 2021...
Rhythm Pharmaceuticals Presents New Data from Phase 2 Basket Study Showing Continued Weight Loss at Up to Nine Months in Patients with HET Obesity on Setmelanotide at ENDO 2021
-- Responders with HET obesity achieved mean weight loss of greater than 12 percent at nine months on setmelanotide therapy...
BridgeBio Pharma Announces Proof-of-Concept Data of Encaleret in ADH1 at the Endocrine Society’s 2021 Annual Meeting
Figure 1 Baseline and Day 5 blood and urine calcium levels – Normalization of Blood Calcium and Urine Calcium in...
Theratechnologies Announces New Data Demonstrating Tesamorelin’s Positive Effect on Immune Response Linked to Liver Inflammation
Data presented at ENDO 2021MONTREAL, March 20, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical...
Chiasma Presents New Positive Data for MYCAPSSA from Phase 3 Trial MPOWERED™ for the Maintenance Treatment of Acromegaly at ENDO 2021
--Data supports MYCAPSSA® as non-inferior to long-acting injectable somatostatin receptor ligands (iSRLs)-- --Data demonstrated patients taking MYCAPSSA had significant improvement...
Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201’s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency
Data show greater GH response in pediatric growth hormone deficiency (PGHD) from LUM-201 than standard GH secretagoguesAUSTIN, Texas, March 20,...
Strongbridge Biopharma plc Presents Detailed Results from Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2021 Annual Meeting of the Endocrine Society (ENDO)
~ As Previously Reported, LOGICS Met its Primary Endpoint with Statistical Significance ~ ~ Strongbridge Recently Submitted a New Drug...